Back to Alzheimers Disease
NCT00829374
NCT00829374
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with mild-to-moderate Alzheimer's disease.
- Your Alzheimer's diagnosis meets a specific standard set of medical guidelines known as DSM-IV-TR criteria (confirm with trial site).
- You scored between 12 and 24 on a standard memory and thinking test called the Mini-Mental State Examination (MMSE).
- You have been taking the Alzheimer's medication donepezil (also known as Aricept) at a steady dose for at least 6 months.
Who may not be able to join:
- Your memory or thinking problems are caused by something other than Alzheimer's disease.
- You have a significant physical problem or disease affecting the structure of your brain.
- You have an unstable or serious ongoing health condition, or serious liver or kidney disease.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Medivation, Inc.
Registry
clinicaltrials_gov
Start date
1 March 2009
Est. completion
1 December 2011
Where this trial is recruiting
🇦🇺 Australia
🇧🇪 Belgium
🇫🇮 Finland
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇳🇿 New Zealand
🇸🇪 Sweden
🇬🇧 United Kingdom
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL); Alzheimer's Disease Assessment Scale - Cognitive Subscale
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.